Basilea Pharmaceutica AG BSLN.SW SIX · Healthcare · Switzerland
CHF 71.00 -1.66% -CHF 1.20
Summary
80 / 100 · Bulios Score
What speaks for it
- Earnings per share grew by 45% a year over the last 3 years.
- Out of every 100 CHF of revenue, 17 CHF is left as net profit.
- It earns 19 CHF a year on every 100 CHF of invested capital.
- The share price is below the Bulios Fair Price.
What to watch
- Earnings per share swing sharply from year to year.
Bulios Scoring describes a company's quality and track record, not its future return. A high score is not a buy signal. Learn more
Score in detailPrice
Is it expensive?
Looks cheapBulios Fair Price is an estimate of a stock's fair value from the Bulios valuation model. It is an input for your own analysis, not investment advice. How does it work?
Today you pay 21.9 CHF for 1 CHF of yearly profit.
Valuation in detailIs it growing?
Yes, fastRevenue (CHF)
Diluted EPS (CHF)
- Analyst estimate
Revenue grew by 13% a year over 5 years. Over the last 3 years it grew by 16% a year. Earnings per share grew by 45% a year over the last 3 years.
Growth in detailDoes it make money?
Income figures for the last 12 months are not available.
Profitability in detailIs it financially healthy?
YesIt holds more cash than debt.
Financial health in detailDoes it pay a dividend?
NoIt pays no dividend.
Dividends in detailWhat do analysts expect?
No coverageNo analyst covers this stock.
Analysts in detail